Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Respiratory syncytial virus (RSV) is a major cause of severe acute respiratory tract infections in infants and the elderly.
• Current prevention relies on hygiene and costly monoclonal antibodies for limited high-risk infants.
• There is a significant global health need for safe and effective RSV vaccines.

Purpose of the Study:

• To review the current state of RSV vaccine research and development.
• To highlight vaccine candidates that have reached the clinical stage.
• To discuss the implications of RSV vaccine research for clinical practice.

Main Methods:

• Review of current scientific literature on RSV vaccine development.
• Focus on vaccine candidates in clinical trials.
• Analysis of different vaccine formats including particle-based, vector-based, subunit, and live-attenuated vaccines.

Main Results:

• Multiple RSV vaccine candidates across various formats are in development, with many in clinical trials.
• Different vaccine platforms show promise for preventing RSV infection.
• Ongoing research aims to address the global health challenge posed by RSV.

Conclusions:

• The development of safe and effective RSV vaccines is a priority.
• Several promising vaccine candidates are advancing through clinical trials.
• Until vaccines are widely available, immune prophylaxis remains crucial for high-risk populations.